Thalidomide regulation of NF-κB proteins limits tregs activity in chronic lymphocytic leukemia

Advances in Clinical and Experimental Medicine

Volumn 23, Issue 1, 2014, Pages 25-32

  Skórka, Katarzyna ^a   Bhattacharya, Nupur ^b   Własiuk, Paulina ^a   Kowal, Małgorzata ^a   Mertens, Daniel ^b,c   Dmoszyńska, Anna ^a   Giannopoulos, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY OF ULM   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Chronic lymphocytic leukemia (CLL); Nucelar factor kappa B (NF B); Regulatory T cells (Treg); Thalidomide; Tumor necrosis factor (TNF)

Indexed keywords

ACETYLSALICYLIC ACID; CD25 ANTIBODY; CD3 ANTIBODY; CD38 ANTIGEN; CD4 ANTIBODY; CELL ANTIBODY; FICOLL; FLUDARABINE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; OLIGONUCLEOTIDE; PROTEIN KINASE ZAP 70; THALIDOMIDE; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; PROTEIN P50; PROTEIN P52; SYNAPTOTAGMIN I;

ADULT; AGED; ARTICLE; CANCER STAGING; CD4+ CD25+ T LYMPHOCYTE; CHEMOLUMINESCENCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DENSITY GRADIENT CENTRIFUGATION; DISEASE EXACERBATION; DNA BINDING; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOLOGICAL PARAMETERS; LYMPHOCYTE DOUBLING TIME; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT RESPONSE; UPREGULATION; CELL ACTIVITY; HUMAN CELL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

AGED; ANTIGENS, CD38; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NF-KAPPA B; T-LYMPHOCYTES, REGULATORY; THALIDOMIDE; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84897517786     PISSN: 18995276     EISSN: None     Source Type: Journal    
DOI: 10.17219/acem/37018     Document Type: Article

References (27)

1. Giannopoulos K, Mertens D, Stilgenbauer S: Treating chronic lymphocytic leukemia with thalidomide and lenalidomide. Expert Opin Pharmacother 2011, 12, 2857-2864.
2. D'Amanto RJ, Loughnan M.S, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 91, 4082-4085. (Pubitemid 24139577)
3. Corral LG, Haslet PA, Muller GW: Differential cytokine modulation and T-cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999, 163, 380-386. (Pubitemid 29295864)
4. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS: Inhibition of NF-κB Activity by thalidomide through Supression of IκB Kinase Activity. J Biol Chem 2001, 276, 22382-22387.
5. Fra̧czek M, Rostowska-Nadolska B, Kapral M, Szota J, Krecicki T, Mazurek U: Microarray Analysis of NF-κB dependent genes in Chronic Rhinosiusitis with Nasal Polyps. Adv Clin Exp Med 2013, 22, 2, 209-217.
6. Skórka K, Giannopoulos K: Budowa i funkcje ja̧drowego czynnika transkrypcyjnego NF kappa B (NF-κB) oraz jego znaczenie w przewlekłej białaczce limfocytowej. Acta Haematologica Polonica 2012, 43, 1, 54-62.
7. Turco MC, Romano MF, Petrella A, Bisogni R, Tassone P, Venuta S: NF-κB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia 2004, 18, 11-17. (Pubitemid 38159433)
8. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ: Modulation of NFκB activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000, 164, 2200-2206. (Pubitemid 30108780)
9. Farahani M, Treweeke AT, Toh CH, Till KJ, Harris RJ, Cawley JC, Zuzel M, Chen H: Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia 2005, 19, 524-530. (Pubitemid 40521154)
10. Endo T, Nisho M., Enzler T, Cottam HB, Fukoda T, James DF, Karin M, Kipps TJ: BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 2007, 109, 703-710. (Pubitemid 46105972)
11. Zaninoni A, Impreiali FG, Pasquini C, Zanella A, Barcellini W: Cytokine modulation of nuclear factor-κB activity in B-chronic lymphocytic leukemia. Exp Hematol 2003, 31,185-190. (Pubitemid 36313259)
12. Hewamana S, Alghazal S, Lin TT: The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008, 111, 4681-4689.
13. Giannopoulos K, Dmoszynska A, Kowal M, Wasik-Szczepanek E, Bojarska-Junak A, Rolinski J, Döhner H, Stilgenbauer S, Bullinger L: Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia 2009, 23, 1771-1778.
14. Krober A, Bloehdorn J, Hafner S, Buhler A, Seiler T, Kienle D, Winkler D, Bangerter M, Schlenk RF, Benner A, Lichter P, Dohner H, Stilgenbauer S: Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006, 24, 969-975. (Pubitemid 46646223)
15. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111, 5446-5456.
16. Giannopoulos K, Schmitt M, Wlasiuk P, Chen J, Bojarska-Junak A, Kowal M, Rolinski J, Dmoszynska A: The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 2008, 22, 222-224.
17. Bhattacharya N, Sarno A, Idler IS, Führer M, Zenz T, Döhner H, Stilgenbauer S, Mertens D: High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay. Int J Cancer 2010, 127, 404-411.
18. Siebenlist U, Franzoso G, Brown K: Structure, regulation and function of NF-κB. Annu Rev Cell Biol 1994, 10, 405-455.
19. Piotrowska A, Iźykowska I, Podhorska-Okołów M, Zabel M, Dziegiel P: Budowa białek z rodziny NF-κB i ich rola w procesie apoptozy. Postȩpy Hig Med Dosw (online) 2008, 62, 64-74.
20. Pierkins ND, Gilmore TD: Good cop, bad cop: the different faces of NF-κB. CellDeath and Differentiation 2006, 13, 759-772.
21. Pickering BM, de Mel S, Lee M, Howell M, Habens F, Dallman CL, Neville LA, Potter KN, Mann J, Mann DA, Johnson PW, Stevenson FK, Packham G: Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 2007, 26, 1166-1177.
22. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC: CD4 (+) CD25 (+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002, 16, 311-323. (Pubitemid 34211969)
23. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002, 3, 135-142. (Pubitemid 34141443)
24. Zhan Y, Gerondakis S, Coghill E, Bourges D, Xu Y, Brady JL, Lew AM: Glucocorticoid-induced TNF receptor expression by T cells is reciprocally regulated by NF-kappaB and NFAT. J Immunol 2008, 15, 5405-5413.
25. Esparza EM, Arch RH: Glucocorticoid-induced TNF receptor, a costimulatory receptor on naive and activated T cells, uses TNF receptor-associated factor 2 in a novel fashion as an inhibitor of NF-kappa B activation. J Immunol 2005, 174, 7875-7882. (Pubitemid 40806297)
26. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE: TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006, 108, 253-261. (Pubitemid 43990636)
27. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, Albitar M: The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002, 100, 1215-1219. (Pubitemid 34864274)